Oracle stock slips after hours as Jefferies sticks with $400 target — what ORCL traders watch next
7 January 2026

Oracle stock slips after hours as Jefferies sticks with $400 target — what ORCL traders watch next

New York, January 6, 2026, 17:53 EST — After-hours

  • ORCL closed up 0.6% Tuesday, then edged lower in after-hours trade.
  • Jefferies reiterated a Buy rating and kept a $400 price target in a 2026 software outlook.
  • Investors are watching Oracle’s near-term dividend timetable and the next earnings update in mid-March.

Oracle shares rose 0.6% to close at $193.75 on Tuesday, after trading between $190.78 and $194.83. The stock was down 0.05% at $193.65 in after-hours trading as of 6:00 p.m. ET.

The moves come as Jefferies kept a bullish call on Oracle, a name that has drawn sharp debate on Wall Street over how quickly its cloud expansion converts into profit. In a sector outlook published on Monday, Jefferies analyst Brent Thill said there was “far more upside than downside” at current levels. MarketWatch

Jefferies flagged Oracle’s push to add data-center capacity for AI workloads as the core swing factor, and said meaningful AI-related revenue should start showing up by fiscal 2027. The firm also noted that OpenAI represents a large share of Oracle’s contract backlog, underscoring how much execution depends on a handful of large customers.

That focus intensified after Oracle’s December quarter forecast missed Wall Street targets and the company raised expectations for fiscal 2026 capital spending, rekindling concerns about how long cash outlays will run ahead of returns. Oracle also reported a sharp jump in remaining performance obligations — a measure of contracted revenue not yet booked — which investors have treated as a key indicator of cloud demand.

Oracle has pitched itself as a bigger supplier of rented computing power for generative AI, competing with Amazon, Microsoft and Google for cloud infrastructure work. “Investors are likely to be more focused on the fundamentals of the AI build-out and its financial implications,” Bernstein analyst Mark Moerdler wrote in a note around Oracle’s last earnings cycle. Reuters

But the path is not clean. A key risk is financing and timing around the data-center buildout, after Reuters reported in December that talks stalled on funding for a major Michigan project tied to Oracle’s AI infrastructure push, adding to scrutiny of debt and spending plans.

Near term, investors will watch Oracle’s dividend calendar: the company declared a $0.50-per-share cash dividend payable on Jan. 23 to shareholders of record on Jan. 9. Oracle also says it expects to announce fiscal third-quarter results in mid-March.

For the next session, traders are likely to track whether ORCL can hold above the low-$190s area after the recent pullback, while looking for any read-through on enterprise cloud demand and AI infrastructure spending across the software group. The next hard date on the tape is Jan. 9, the record date for Oracle’s dividend.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Xylem

NYSE: XYL 95 / 100
#2 BUY

AerCap

NYSE: AER 93 / 100
#3 BUY ON WEAKNESS

Visa

NYSE: V 90 / 100
#4 TACTICAL BUY

Chevron

NYSE: CVX 87 / 100
#5 ACCUMULATE

UPS

NYSE: UPS 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.
AppLovin stock drops even after Benchmark names it a 2026 top idea
Previous Story

AppLovin stock drops even after Benchmark names it a 2026 top idea

Eli Lilly stock rises after hours on Nimbus obesity pill deal as Ventyx talks surface
Next Story

Eli Lilly stock rises after hours on Nimbus obesity pill deal as Ventyx talks surface